title: Prime time for drug eluting balloons in SFA interventions?
abstract: Peripheral arterial disease most commonly affects the femoropopliteal segment. Despite enormous improvements in device and treatment technology the long-term patency rate and clinical benefit of endovascular treatment in the respective vascular bed is not satisfying. Drug coated balloon technology as a treatment option in femoropopliteal disease has shown encouraging results in first-in-man trials, which have now been proven in large randomized controlled trials.
authors.affiliation: Division of Angiology Medical University of Graz, Graz, Austria - marianne.brodmann@medunigraz.at.
authors.forename: M
authors.initials: M
authors.lastname: Brodmann
mesh_terms: D000800:Angioplasty, Balloon / Q000009:adverse effects / Q000191:economics / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000191:economics; D020099:Coated Materials, Biocompatible / Q000191:economics; D004867:Equipment Design; D005263:Femoral Artery / Q000503:physiopathology; D017048:Health Care Costs; D006801:Humans; D058729:Peripheral Arterial Disease / Q000175:diagnosis / Q000191:economics / Q000503:physiopathology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome; D062666:Vascular Access Devices / Q000191:economics; D014654:Vascular Patency
chemical_list: D002317:Cardiovascular Agents; D020099:Coated Materials, Biocompatible